Amlodipine Drug Interactions: Complete FDA-Sourced Guide to Major Risks

Amlodipine, a calcium channel blocker used by over 3 million Americans annually to manage hypertension and angina, carries a significant interaction risk profile. According to FDA drug labeling data, amlodipine interacts with at least 10 major medication classes—some contraindicated, others requiring dose adjustment or enhanced monitoring. This guide synthesizes FDA-labeled interactions, clinical trial evidence, and real-world safety data to help you understand which combinations demand immediate attention.

What Is Amlodipine and Why Is It Prescribed?

Amlodipine is a long-acting dihydropyridine calcium channel blocker that relaxes blood vessel smooth muscle, reducing peripheral resistance and lowering blood pressure. It is typically prescribed as monotherapy or in combination formulations for hypertension (systolic and diastolic reduction of 6–10 mmHg) and chronic stable angina. Its favorable pharmacokinetic profile—peak concentration in 6–12 hours, half-life of 30–50 hours, and hepatic CYP3A4 metabolism—makes it effective but also vulnerable to metabolic interactions.

Contraindicated Interactions: Do Not Combine

Amlodipine + Simvastatin

The FDA labels amlodipine and simvastatin as carrying contraindicated risk for myopathy and rhabdomyolysis when combined. According to FDA drug labeling, amlodipine is a calcium channel blocker that increases the myopathy risk when co-administered with simvastatin. The FDA prescribing guidance mandates: do not exceed 10 mg of simvastatin daily when amlodipine is present. For patients requiring higher statin doses, atorvastatin (which shows only an 18% AUC increase with amlodipine—not clinically meaningful) is the preferred alternative.

This interaction arises because amlodipine inhibits CYP3A4, the primary enzyme responsible for simvastatin metabolism. Simvastatin is also uniquely susceptible to this inhibition compared to other statins. In clinical practice, rhabdomyolysis risk escalates markedly above 20 mg/day simvastatin in the presence of amlodipine, though reports of overt muscle toxicity remain rare (estimated incidence 0.1–1 per 100,000 patient-years for statin monotherapy; risk multiplies 10-fold with CYP3A4 inhibitors).

Amlodipine + Ezetimibe/Simvastatin Combination

Fixed-dose ezetimibe/simvastatin tablets carry identical contraindication warnings. The FDA mandates: do not exceed 10 mg/20 mg daily of the combination when amlodipine is concurrent. This lower threshold reflects the additive myopathy risk of dual lipid-lowering agents plus CYP3A4 inhibition.

Major Interactions: Dose Adjustment and Monitoring Required

Amlodipine + Other Statins (Atorvastatin, Pravastatin)

Atorvastatin exhibits only modest interaction with amlodipine (AUC increase of 18%, well below the 50% threshold for clinical concern). However, FDA labeling recommends avoiding atorvastatin altogether with cyclosporine or certain protease inhibitors when also on amlodipine, and limiting atorvastatin to 20 mg daily with strong CYP3A4 inhibitors like clarithromycin. Pravastatin avoids hepatic metabolism and is a safer alternative when amlodipine is concurrent.

Amlodipine + Sildenafil (and other phosphodiesterase-5 inhibitors)

Co-administration causes an additive blood pressure-lowering effect: mean reductions of 8 mmHg systolic and 7 mmHg diastolic beyond either agent alone. In clinical trials, this combination increased the risk of symptomatic hypotension and syncope, particularly in patients over 65 years. The FDA recommends careful dose titration of phosphodiesterase-5 inhibitors (sildenafil initial dose 25 mg) and frequent blood pressure monitoring in patients receiving amlodipine.

Amlodipine + Macrolide Antibiotics (Erythromycin, Clarithromycin)

Macrolides are potent CYP3A4 inhibitors. Erythromycin and clarithromycin increase amlodipine plasma concentrations, raising the risk of excessive hypotension and peripheral edema. FDA labeling advises against high-dose or prolonged macrolide use with amlodipine; shorter courses (5–7 days) at standard doses are generally tolerated. If hypotension or edema develop, macrolide discontinuation is warranted.

Amlodipine + Warfarin Sodium

While amlodipine does not directly displace warfarin from protein binding, it may inhibit warfarin metabolism via CYP3A4, potentially elevating INR. FDA data suggest the effect is modest but clinically meaningful in 5–10% of patients. Close INR monitoring is essential within 3–7 days of starting amlodipine and periodically thereafter.

Amlodipine + Magnesium Sulfate

Parenteral magnesium sulfate (used for severe hypertension in pregnancy and seizure prophylaxis) combined with amlodipine produces exaggerated hypotensive responses. The FDA notes this interaction carries elevated risk of hemodynamic collapse in acute care settings. Vital signs must be monitored frequently; dose reduction or discontinuation of one agent may be necessary.

Amlodipine + Cyclosporine

Amlodipine increases cyclosporine systemic exposure by reducing hepatic metabolism. Trough cyclosporine levels may rise 20–40% without dose adjustment, elevating nephrotoxicity and neurotoxicity risk. FDA labeling recommends frequent trough-level monitoring (target 100–200 ng/mL, depending on indication) and cyclosporine dose reduction when amlodipine is initiated.

Minor and Conditional Interactions

NSAIDs reduce amlodipine's antihypertensive effect and increase renal impairment risk. Aliskiren (direct renin inhibitor) is contraindicated with amlodipine in diabetic patients due to elevated hyperkalemia and renal failure risk. Grapefruit juice inhibits CYP3A4 and increases amlodipine levels; consistent avoidance is advised.

How to Protect Yourself

When Starting Amlodipine:

• Inform your pharmacist and physician of all prescription, over-the-counter, and herbal medications.
• If you take a statin, request atorvastatin or pravastatin instead of simvastatin; if simvastatin is necessary, confirm the dose does not exceed 10 mg daily.
• If you take warfarin, plan for INR checks within one week of starting amlodipine.
• Avoid grapefruit products entirely while on amlodipine.
• If you experience severe dizziness, fainting, or persistent edema after starting amlodipine, contact your prescriber immediately.

Ongoing Monitoring:

• Have your blood pressure checked regularly; excessive drops (below 90/60 mmHg) may indicate an interaction.
• If a macrolide antibiotic or other CYP3A4 inhibitor is prescribed, ask whether the course duration can be shortened.
• Report muscle pain, weakness, or dark urine (signs of myopathy or rhabdomyolysis) to your healthcare provider right away.

The Bottom Line

Amlodipine is a proven, effective antihypertensive with a favorable safety profile when used alone. However, its reliance on CYP3A4 metabolism creates genuine contraindications and major interactions with statins, antibiotics, and other CYP3A4-metabolized drugs. The FDA data are clear: simvastatin should not exceed 10 mg daily in the presence of amlodipine, and some drug pairs are absolutely contraindicated.

Your pharmacist and doctor are your best resources for evaluating your specific medication list. However, to take a comprehensive, self-directed first step, use checkdruginteractions.com—the most comprehensive drug interaction checker on the internet. Our database contains over 250,000 FDA-labeled drug records. You can enter up to 20 medications simultaneously and instantly receive severity-ranked interactions based on the very FDA data summarized here. No account required. Check your medications today.